Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Oncotarget. 2011; 2: 135-164
- Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations.Onco Targets Ther. 2016; 9: 3711-3726
- Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.Clin Cancer Res. 2007; 13: 1576-1583
- The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.Clin Cancer Res. 2010; 16: 1613-1623
- Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice.J Clin Oncol. 2014; 32: 10018
- Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas.N Engl J Med. 2016; 375: 2550-2560
- Selumetinib in children with inoperable plexiform neurofibromas.N Engl J Med. 2020; 382: 1430-1442
US Food & Drug Administration. Prescribing Information KOSELUGO (selumetinib). Accessed September 28, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf.
- Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.J Clin Oncol. 2008; 26: 2139-2146
- A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.Cancer Chemother Pharmacol. 2011; 68: 1619-1628
- Comparison of the pharmacokinetics of the Phase II and Phase III capsule formulations of selumetinib and the effects of food on exposure: results from two randomized crossover trials in healthy male subjects.Clin Ther. 2017; 39 (e2261): 2260-2275
- Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis.Eur J Clin Pharmacol. 2017; 73: 717-726
- Pharmacokinetics of a single oral dose of the MEK1/2 inhibitor selumetinib in subjects with end-stage renal disease or varying degrees of hepatic impairment compared with healthy subjects.J Clin Pharmacol. 2017; 57: 592-605
- Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.Cancer Chemother Pharmacol. 2021; 88: 189-202
European Medicines Agency. Koselugo (selumetinib) Summary of Product Characteristics. https://www.ema.europa.eu/en/medicines/human/EPAR/koselugo#product-information-section Accessed February 1, 2022.